NCT07580547

Brief Summary

DISPARITY-AF is a prospective, single-center, observational registry designed to characterize the sex-based disparities in the electrophysiological substrate driving Atrial Fibrillation (AF). While standard Pulmonary Vein Isolation (PVI) is the cornerstone of AF ablation, women consistently experience lower long-term success rates. This study tests the hypothesis that women harbor a significantly higher burden of unmapped, extra-pulmonary vein (extra-PV) AF initiation sites compared to men. In 100 consecutive patients undergoing first-time PVI, comprehensive biatrial repolarization mapping will be performed using programmed electrical stimulation (PES) to measure the atrial effective refractory period (AERP) in multiple atrial sites immediately after successful PVI. All mapping systems and multielectrode catheters utilized in this study are clinically approved and used routinely in our center. Identified steep repolarization gradients (SRGs) and AF initiation sites will be documented but not ablated. Patients will undergo intensive 1-year clinical follow-up to test the secondary hypothesis that patients with untreated extra-PV SRG/AF initiation sites have a significantly higher rate of AF recurrence.

Trial Health

63
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
100

participants targeted

Target at P50-P75 for not_applicable

Timeline
23mo left

Started Apr 2026

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress5%
Apr 2026Apr 2028

Study Start

First participant enrolled

April 19, 2026

Completed
9 days until next milestone

First Submitted

Initial submission to the registry

April 28, 2026

Completed
14 days until next milestone

First Posted

Study publicly available on registry

May 12, 2026

Completed
11 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 19, 2027

Expected
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

April 19, 2028

Last Updated

May 12, 2026

Status Verified

May 1, 2026

Enrollment Period

1 year

First QC Date

April 28, 2026

Last Update Submit

May 5, 2026

Conditions

Keywords

AblationAtrial FibrillationGenderSexDisparity

Outcome Measures

Primary Outcomes (1)

  • Spatial distribution and frequency of extra-PV sites and AF initiation sites in both atria following standard PVI.

    Number of extra-PV sites and AF initiations for every patient (N per patient)

    During procedure

Secondary Outcomes (1)

  • Freedom from AF and AT at one year.

    During 12 month follow up period.

Study Arms (1)

PVI ablation and identifying extra-PV SRG sites

OTHER

Men and women undergoing first time PVI ablation for identification of extra-PV SRG sites.

Device: Identifying extra-PV SRG sites

Interventions

After performing PVI as standard of care, mapping of both atria will be performed to locate extra-PV SRG sites.

PVI ablation and identifying extra-PV SRG sites

Eligibility Criteria

Age18 Years+
Sexall(Gender-based eligibility)
Gender Eligibility DetailsThe study requires 50 male patients and 50 female patients.
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Age 18 years or older.
  • Male or Female sex.
  • Symptomatic paroxysmal or persistent AF indicated for a first-time catheter ablation.
  • Ability to provide written informed consent.

You may not qualify if:

  • Prior catheter ablation for AF or surgical MAZE.
  • Long-standing persistent AF (\>12 months).
  • Presence of intracardiac thrombus or contraindication to systemic anticoagulation.
  • Pregnant women and patients not able to provide an informed consent

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Shamir Medical Center

Be’er Ya‘aqov, Israel

Location

MeSH Terms

Conditions

Atrial FibrillationCoitus

Condition Hierarchy (Ancestors)

Arrhythmias, CardiacHeart DiseasesCardiovascular DiseasesPathologic ProcessesPathological Conditions, Signs and SymptomsSexual BehaviorBehavior

Central Study Contacts

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
OTHER
Intervention Model
SINGLE GROUP
Model Details: In 100 consecutive patients undergoing first-time PVI, comprehensive biatrial repolarization mapping will be performed using programmed electrical stimulation (PES) to measure the atrial effective refractory period (AERP) in multiple atrial sites immediately after successful PVI. All mapping systems and multielectrode catheters utilized in this study are clinically approved and used routinely in our center. Identified steep repolarization gradients (SRGs) and AF initiation sites will be documented but not ablated. Patients will undergo intensive 1-year clinical follow-up to test the secondary hypothesis that patients with untreated extra-PV SRG/AF initiation sites have a significantly higher rate of AF recurrence.
Sponsor Type
OTHER GOV
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Cardiologist in Electrophysiology Unit

Study Record Dates

First Submitted

April 28, 2026

First Posted

May 12, 2026

Study Start

April 19, 2026

Primary Completion (Estimated)

April 19, 2027

Study Completion (Estimated)

April 19, 2028

Last Updated

May 12, 2026

Record last verified: 2026-05

Locations